Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02055586 · ClinicalTrials.gov registry record
FLT-PET/MRI for Early Response Monitoring to Novel Cancer Therapeutic Agents
A clinical trial, sponsored by Case Comprehensive Cancer Center.
- Completed
- Registry status
- 10
- Enrollment target
NCT02055586 is a clinical trial that has completed, run by Case Comprehensive Cancer Center. The registered enrollment target is 10 participants.
The verdict
NCT02055586 has completed, sponsored by Case Comprehensive Cancer Center.
- COMPLETED
- Registry status
- 10 participants
- Enrollment target
Study Summary
This pilot clinical trial studies fluorine F 18 fluorothymidine (FLT)-positron emission tomography/magnetic resonance imaging (PET/MRI) in measuring early response in patients with metastatic solid tumors receiving treatment that blocks blood flow to the tumor. Diagnostic procedures, such as FLT-PET/MRI, may help measure a patient's response earlier during treatment.
Interventions
- OTHER fluorine F 18 fluorothymidine
- DEVICE positron emission tomography
- DEVICE magnetic resonance imaging
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2013-10-22 |
| Est. Completion | 2017-12-27 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02055586
The ClinicalTrials.gov registry entry for NCT02055586 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Case Comprehensive Cancer Center, which has 407 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which fluorine F 18 fluorothymidine is the first listed.
NCT02055586 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02055586 about?
NCT02055586 is a clinical study titled "FLT-PET/MRI for Early Response Monitoring to Novel Cancer Therapeutic Agents". This pilot clinical trial studies fluorine F 18 fluorothymidine (FLT)-positron emission tomography/magnetic resonance imaging (PET/MRI) in measuring early response in patients with metastatic solid tumors receiving treatment that blocks blood flow to the tumor. Diagnostic procedures, such as FLT-PET...
What is the current status of trial NCT02055586?
This trial is currently completed. The enrollment target is 10 participants. The study started on 2013-10-22. Estimated completion is 2017-12-27.
What interventions are being tested in trial NCT02055586?
The interventions under investigation include: fluorine F 18 fluorothymidine (OTHER), positron emission tomography (DEVICE), magnetic resonance imaging (DEVICE).
Who is sponsoring clinical trial NCT02055586?
This trial is sponsored by Case Comprehensive Cancer Center, which has 407 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.